Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced a new enterprise agreement with Bioforum, a biometrics CRO that ...
Boomi ™, the intelligent integration and automation leader, today announced the addition of two seasoned executives to its ...
OAG, the world’s leading data platform for the global travel industry, is delighted to announce Filip Filipov as the company’s new Chief Operating Officer.
Chennai, Tamil Nadu, India: The A.P. Moller Relief Foundation, a Danish philanthropic foundation, donated US$ 750,000 to establish a major infrastructure upgrade in the form of a Full Mission ...
IDFC FIRST Bank, today announced the launch of startup lounge an exclusive space designed to support entrepreneurs and empower early-stage startups in India. Located in Koramangala, Bangalore, this ...
Newark, Calif., United States & Bangalore, Karnataka, India: Ohmium International (“Ohmium”), a leading green hydrogen company that designs, manufactures, and deploys advanced Proton Exchange Membrane ...
PARIS, France & Geneva, Switzerland & CHICAGO, Oakland, Calif., United States: McKay Brothers (“McKay” or “the Company”), a market leader in ultra-low latency market data and wireless networks, today ...
ABB India, a global leader in electrification and automation, has announced the launch of ABB-free@home® in India, a Smart Home automation system with enhanced interoperability. This cutting-edge and ...
In celebration of the 60th anniversary of the International Union for Conservation of Nature (IUCN) Red List of Threatened ...
Bureau Veritas contributes to accelerating the energy transition by providing customers across the energy sector with end-to-end solutions to meet the immediate and future challenges of developing and ...
On November 14th, 2024, the Indigenomics NOW forum is convening Indigenous business leadership, entrepreneurs, and allies from around the world in a virtual gathering that asks: How can we build ...
Phase III MANEUVER study met primary endpoint, with an objective response rate at week 25 of 54.0% for pimicotinib versus 3.2% for placebo (p<0.0001) Statistically significant and clinically ...